Health Canada is currently examining nine submissions for generic versions of popular weight loss medications, which experts believe could lead to reduced prices. These submissions pertain to generic forms of semaglutide, the key component in Novo Nordisk’s injectable drugs Ozempic and Wegovy, approved by Health Canada for treating diabetes and weight loss. Semaglutide falls under a class of medications known as glucagon-like peptide-1 (GLP-1) therapies, mimicking a natural gut hormone to regulate blood sugar levels, slow digestion, and increase satiety. Common side effects may include nausea, vomiting, diarrhea, stomach pain, fatigue, constipation, and headaches.
Canada stands out as the only country where Novo Nordisk’s patent for semaglutide drugs has expired, allowing for the end of “regulatory exclusivity” on Jan. 4. Consequently, Canada could potentially offer a more cost-effective alternative to Ozempic and Wegovy to patients with prescriptions, though immediate availability is unlikely. The approval and pricing details of these drugs are being closely monitored.
In the U.S., Novo Nordisk has announced the availability of a pill version of Wegovy, with higher doses expected to be accessible by the end of the week. While inquiries about the availability of the Wegovy pill in Canada were redirected to the U.S. media release, Health Canada has not confirmed the receipt of any application for a pill form of Wegovy or its generic equivalent.
Generic versions of medications are deemed pharmaceutically equivalent to brand-name drugs by Health Canada, which rigorously evaluates safety, quality, and effectiveness criteria before granting authorization. The evaluation process for generic semaglutide drugs is considered more intricate due to the biological processes involved in the drug’s original development. Pricing factors include the drug’s formulation, availability of branded versions, market competition with generic alternatives, and dosing requirements.
Experts anticipate that the introduction of cheaper alternatives may not occur immediately, with potential approvals more likely in the summer rather than early in the year. The approval of generic versions is expected to significantly reduce costs for patients currently paying substantial amounts for GLP-1 medications, enhancing accessibility for individuals seeking weight loss treatment. Companies such as Sandoz Canada, Apotex, Teva Canada, Taro Pharmaceuticals, and Aspen Pharmacare Canada are among those seeking Health Canada’s review for generic submissions.